Efficacy of SGLT2 inhibitor (dapagliflozin or ipragliflozin) as an add-on therapy in patients with type 2 diabetes mellitus: A retrospective study

Trial Profile

Efficacy of SGLT2 inhibitor (dapagliflozin or ipragliflozin) as an add-on therapy in patients with type 2 diabetes mellitus: A retrospective study

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Dapagliflozin (Primary) ; Ipragliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 30 Jun 2017 New trial record
    • 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association
    • 01 Jun 2017 Results published in the Diabetes Therapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top